Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.
Study Goal
The researchers aimed to review the efficacy and safety profiles of melatonin receptor agonists (ramelteon, prolonged-release melatonin, agomelatine, and tasimelteon) for treating insomnia, depression, and circadian rhythm sleep-wake disorders, as well as their effects on comorbid conditions.
Results Summary
The study found that melatonin receptor agonists are effective for treating sleep-wake disorders and also have beneficial effects on comorbid neurological, psychiatric, cardiovascular, and metabolic conditions. The review highlights the importance of enhancing physiological sleep in comorbid conditions.
Population
Patients with insomnia, depression, and circadian rhythm sleep-wake disorders, including those with comorbid medical conditions.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin receptors agonists (ramelteon, prolonged-release melatonin, agomelatine and tasimelteon) | neutral | insomnia, depression and circadian rhythms sleep-wake disorders | - | - | have recently become available for the treatment of | #1 |
melatonin receptor agonists | increase | comorbid neurological, psychiatric, cardiovascular and metabolic symptomatology beyond sleep regulation | - | - | Beneficial effects of | #2 |
enhancing physiological sleep | increase | comorbid conditions | - | - | beneficial value of | #3 |
Several melatonin receptors agonists (ramelteon, prolonged-release melatonin, agomelatine and tasimelteon) have recently become available for the treatment of insomnia, depression and circadian rhythms sleep-wake disorders. The efficacy and safety profiles of these compounds in the treatment of the indicated disorders are reviewed. Accumulating evidence indicates that sleep-wake disorders and co-existing medical conditions are mutually exacerbating. This understanding has now been incorporated into the new Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). Therefore, when evaluating the risk/benefit ratio of sleep drugs, it is pertinent to also evaluate their effects on wake and comorbid condition. Beneficial effects of melatonin receptor agonists on comorbid neurological, psychiatric, cardiovascular and metabolic symptomatology beyond sleep regulation are also described. The review underlines the beneficial value of enhancing physiological sleep in comorbid conditions.